HPV16 E7‐induced upregulation of KDM2A promotes cervical cancer progression by regulating miR‐132–radixin pathway

Ou, Rongying; Zhu, Linyu; Zhao, Liang; Li, Wenfeng; Tao, Fengxing; Lu, Yiyi; He, Qiaojun; Lǐ, Jiànróng; Ren, Yi; Xu, Yunsheng

doi:10.1002/jcp.27080

Cited by 30 publications

(23 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In pathological processes, such as gastric cancer and glioblastoma, LINC00460, microRNA (miRNA/miR)-29b, miR-134-5p and miR-3666 directly bind to the KDM2A promoters to regulate KDM2A expression (24,(28)(29)(30)(31). Inflammation, hypoxia or reactive oxygen species production promote KDM2A expression (26,32), and upregulation of KDM2A induced by human papilloma virus (HPV)16E7 promotes tumorigenesis and progression of cervical cancer (33). Metformin activates the AMPK signaling pathway and decreases intracellular succinic acid levels, while activation of KDM2A decreases ribosomal RNA (rRNA) transcription (27).…”

Section: Kdm2a Expression and Regulationmentioning

confidence: 99%

Histone demethylase KDM2A: Biological functions and clinical values (Review)

Liu

Lin

2021

Exp Ther Med

View full text Add to dashboard Cite

Section: Kdm2a Expression and Regulationmentioning

confidence: 99%

Histone demethylase KDM2A: Biological functions and clinical values (Review)

Liu

Lin

2021

Exp Ther Med

View full text Add to dashboard Cite

“…Among the five hallmarks of cancer [76] identified in this study (Figure 5), the hallmark that showed the most DEmiRNAs was sustained proliferative signaling, with 18 downregulated tsmiRs and six upregulated oncomiRs in patients with CC. Among the different miRNAs identified in this pathway, Ou et al [49] found that miR-132 can play an important role in regulating the progression of cervical cancer, contributing to the growth and progression of cervical cancer through the depression of the expression of the RDX oncogene as underlying mechanism. On the other hand, it was seen that miR-411 inhibited the progression of cervical cancer when interacting directly with STAT3; the authors also indicated that this miRNA may represent a new potential therapeutic target and prognostic marker for patients with this disease [50].…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of MicroRNAs Involved in Cervical Cancer Progression

Causin

Freitas

Filho

et al. 2021

Cells

View full text Add to dashboard Cite

To obtain a better understanding on the role of microRNAs in the progression of cervical cancer, a systematic review was performed to analyze cervical cancer microRNA studies. We provide an overview of the studies investigating microRNA expression in relation to cervical cancer (CC) progression, highlighting their common outcomes and target gene interactions according to the regulatory pathways. To achieve this, we systematically searched through PubMed MEDLINE, EMBASE, and Google Scholar for all articles between April 2010 and April 2020, in accordance with the PICO acronym (participants, interventions, comparisons, outcomes). From 27 published reports, totaling 1721 cases and 1361 noncancerous control tissue samples, 26 differentially expressed microRNAs (DEmiRNAs) were identified in different International Federation of Gynecology and Obstetrics (FIGO) stages of cervical cancer development. It was identified that some of the dysregulated microRNAs were associated with specific stages of cervical cancer development. The results indicated that DEmiRNAs in different stages of cervical cancer were functionally involved in several key hallmarks of cancer, such as evading growth suppressors, enabling replicative immortality, activation of invasion and metastasis, resisting cell death, and sustained proliferative signaling. These dysregulated microRNAs could play an important role in cervical cancer’s development. Some of the stage-specific microRNAs can also be used as biomarkers for cancer classification and monitoring the progression of cervical cancer.

show abstract

“…In non-small cell lung cancer (NSCLC), Wagner et al demonstrated that KDM2A was overexpressed and could promote the proliferation and metastasis of NSCLC cells by regulating the activity of ERK1/2 pathway, which is correlated with a poor prognosis of NSCLC patients [8]. An up-regulated expression of KDM2A was also shown to play a critical role in the onset and progression of cervical cancer and promote the proliferation and invasion of cervical cancer cells [10,20]. In addition, Xu et al found that KDM2A might be an important regulator of cell proliferation and cell cycle via impacting TGF-β signaling pathway [21].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have observed KDM2A functioning as an oncogene, and its expression was elevated in lung cancer, breast cancer, and cervical cancer to promote tumorigenesis and proliferation of cancer cells [7][8][9][10]. On the contrary, Frescas et al found that KDM2A expression was often decreased in prostate cancer compared with normal prostate tissue [11].…”

Section: Introductionmentioning

confidence: 99%

Lysine-specific demethylase 2A gene expression in clear cell renal cell carcinoma and its clinical significance

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundOur study aimed to explore the expression of lysine-specific demethylase 2A (KDM2A) in clear cell renal cell carcinoma (ccRCC) and its relationship with clinical features of ccRCC.MethodsA total of 50 patients with ccRCC were included. KDM2A expression was assessed by real-time PCR and immunohistochemistry (IHC). The correlations of KDM2A protein expression with clinicopathological parameters and survival rate were further verified.ResultsThe KDM2A mRNA expression was significantly higher in ccRCC tissues than para cancer samples (P<0.05). KDM2A protein was mainly expressed in the nucleus of tumor cells. Fifty (100%) of the ccRCC samples were immunopositive, 90% of which all showed high expression of KDM2A. Compared with para cancer tissues, ccRCC samples showed a larger proportion of high KDM2A expression in the overall and most stratified analysis (P<0.05). KDM2A protein expression was positively correlated with TNM stage (r = 0.307, P = 0.030), proteinuria (r = 0.385, P = 0.006), and urine erythrocyte (r = 0.307, P = 0.030). Moreover, Kaplan-Meier survival analysis revealed that higher expression of KDM2A in ccRCC patients was associated with lower survival rate (P = 0.004).ConclusionsOur findings provided the first evidence that KDM2A could be used as a promising diagnostic and prognostic biomarker in ccRCC patients.

show abstract

HPV16 E7‐induced upregulation of KDM2A promotes cervical cancer progression by regulating miR‐132–radixin pathway

Abstract: Our results suggest a function for KDM2A in cervical cancer progression and suggest its candidacy as a new prognostic biomarker and target for clinical management of cervical cancer.

Cited by 30 publications

References 40 publications

Histone demethylase KDM2A: Biological functions and clinical values (Review)

Histone demethylase KDM2A: Biological functions and clinical values (Review)

A Systematic Review of MicroRNAs Involved in Cervical Cancer Progression

Lysine-specific demethylase 2A gene expression in clear cell renal cell carcinoma and its clinical significance

Contact Info

Product

Resources

About